ERBB3 and familial pancreatic carcinoma: In pancreatic cancer xenografts, 9F7-F11 induced tumor regression.[140] GE-huMab-HER3 is a glycoengineered anti-HER3 antibody that enhances antibody-dependent cell-mediated cytotoxicity and increases antitumor effect compared to the non-glycoengineered variant of the antibody WT-huMab-HER3.[141] GSK2849330 is a glycoengineered anti-HER3 monoclonal antibody that increases both complement-mediated and antibody-dependent cell-mediated cytotoxicity (CDC).[142] Phase I studies of GSK2849330 are ongoing (NCT01966445, NCT02345174) (Table 4).